Teamwork Financial Advisors LLC Has $724,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

by · The Cerbat Gem

Teamwork Financial Advisors LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 91.3% during the third quarter, HoldingsChannel.com reports. The fund owned 6,077 shares of the company’s stock after selling 63,393 shares during the period. Teamwork Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $724,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Armstrong Fleming & Moore Inc raised its position in shares of Novo Nordisk A/S by 7.1% in the third quarter. Armstrong Fleming & Moore Inc now owns 7,532 shares of the company’s stock valued at $897,000 after purchasing an additional 500 shares during the period. Good Life Advisors LLC raised its holdings in Novo Nordisk A/S by 8.7% in the 3rd quarter. Good Life Advisors LLC now owns 28,655 shares of the company’s stock worth $3,412,000 after acquiring an additional 2,293 shares during the period. Naviter Wealth LLC lifted its position in Novo Nordisk A/S by 1.1% during the 3rd quarter. Naviter Wealth LLC now owns 62,589 shares of the company’s stock worth $7,452,000 after acquiring an additional 684 shares during the last quarter. Mezzasalma Advisors LLC boosted its holdings in Novo Nordisk A/S by 4.7% during the third quarter. Mezzasalma Advisors LLC now owns 24,007 shares of the company’s stock valued at $2,859,000 after acquiring an additional 1,085 shares during the period. Finally, Bfsg LLC grew its position in shares of Novo Nordisk A/S by 97.1% in the third quarter. Bfsg LLC now owns 86,617 shares of the company’s stock valued at $10,313,000 after purchasing an additional 42,662 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. Finally, BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.50.

Read Our Latest Report on NVO

Novo Nordisk A/S Stock Performance

NVO opened at $118.22 on Friday. The stock has a market cap of $530.52 billion, a PE ratio of 40.77, a P/E/G ratio of 1.53 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $92.94 and a 1 year high of $148.15. The stock’s 50 day simple moving average is $128.79 and its 200-day simple moving average is $131.72. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is 24.83%.

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).